WG
JANX icon

Winton Group’s Janux Therapeutics JANX Stock Holding History

Winton Group’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.39M Buy
90,300
+21,800
+32% +$316K 0.04% 408
2026
Q1 		$952K Buy
68,500
+36,700
+115% +$503K 0.03% 552
2025
Q4 		$439K Buy
+31,800
New +$748K 0.02% 662

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Winton Group's JANX Position: Q2 2026 in Review

Winton Group increased its Janux Therapeutics (JANX) stake by 32% in Q2 2026, buying an estimated $316K and bringing the position to 90,300 shares worth $1.39M. The position accounts for 0.04% of the portfolio, ranked #408.

Winton Group first reported a position in JANX in Q4 2025 and has held it in 3 quarters since. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Winton Group held 90,300 shares of Janux Therapeutics worth $1.39M as of Q2 2026.
  • Winton Group bought 21,800 Janux Therapeutics shares in Q2 2026, an estimated $316K.
  • Janux Therapeutics made up 0.04% of Winton Group's portfolio in Q2 2026, its #408 holding.
  • Winton Group first reported a position in Janux Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.